Compartmental modeling of transdermal iontophoretic transport II: In vivo model derivation and application

Pharmaceutical Research

Volumn 22, Issue 3, 2005, Pages 335-346

  Nugroho, Akhmad Kharis ^a,b   Della Pasqua, Oscar ^a   Danhof, Meindert ^a   Bouwstra, Joke A ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

Alniditan; GRF; R apomorphine; Skin release rate constant; Steady state flux

Indexed keywords

ALNIDITAN; APOMORPHINE; GROWTH HORMONE RELEASING FACTOR;

ANIMAL EXPERIMENT; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG RELEASE; DRUG TRANSPORT; HEMOCONCENTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IONTOPHORESIS; KINETICS; NONHUMAN; PARAMETER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIMULATION; SKIN; STEADY STATE; SYSTEMIC CIRCULATION; TECHNIQUE; TIME;

ADMINISTRATION, CUTANEOUS; ANIMALS; GUINEA PIGS; IONTOPHORESIS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 17644390223     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-004-1870-2     Document Type: Article

References (23)

1. A. K. Nugroho, O. Della-Pasqua, M. Danhof, and J. A. Bouwstra. Compartmental modeling of transdermal iontophoretic transport: I. In vitro model derivation and application. Pharm. Res. 21:1974-1984 (2004).
2. G. L. Li, M. Danhof, P. M. Frederik, and J. A. Bouwstra. Pre-treatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro. Pharm. Res. 20:653-659 (2003).
3. M. S. Roberts, P. M. Lai, and Y. G. Anissimov. Epidermal iontophoresis: I. Development of the ionic mobility-pore model. Pharm. Res. 15:1569-1578 (1998).
4. P. M. Lai and M. S. Roberts. Epidermal iontophoresis: II. Application of the ionic mobility-pore model to the transport of local anesthetics. Pharm. Res. 15:1579-1588 (1998).
5. J. B. Phipps and J. R. Gyory. Transdermal ion migration. Adv. Drug Deliv. Rev. 9:137-176 (1992).
6. M. J. Pikal. Transport mechanisms in iontophoresis. I. A theoretical model for the effect of electroosmotic flow on flux enhancement in transdermal iontophoresis. Pharm. Res. 7:118-126 (1990).
7. M. J. Pikal and S. Shah. Transport mechanisms in iontophoresis. II. Electroosmotic flow and transference number measurements for hairless mouse skin. Pharm. Res. 7:213-221 (1990).
8. M. J. Pikal and S. Shah. Transport mechanisms in iontophoresis. III. An experimental study of the contributions of electroosmotic flow and permeability change in transport of low and high molecular weight solutes. Pharm. Res. 7:222-229 (1990).
9. J. E. Riviere, B. Sage, and P. L. Williams. Effects of vasoactive drugs on transdermal lidocaine iontophoresis. J. Pharm. Sci. 80:615-620 (1991).
10. J. E. Riviere, P. L. Williams, R. S. Hillman, and L. M. Mishky. Quantitative prediction of transdermal iontophoretic delivery of arbutamine in humans with the in vitro isolated perfused porcine skin flap. J. Pharm. Sci. 81:504-507 (1992).
11. M. C. Heit, P. L. Williams, F. L. Jayes, S. K. Chang, and J. E. Riviere. Transdermal iontophoretic peptide delivery: in vitro and in vivo studies with luteinizing hormone releasing hormone. J. Pharm. Sci. 82:240-243 (1993).
12. M. Gibaldi and D. Perrier. Pharmacokinetics. Marcel Dekker, New York, 1982.
13. P. Singh, M. S. Roberts, and H. I. Maibach. Modelling of plasma levels of drugs following transdermal iontophoresis. J. Control. Rel. 33:293-298 (1995).
14. S. Kumar, H. Char, S. Patel, D. Piemontese, A. W. Malick, K. Iqbal, E. Neugroschel, and C. R. Behl. In vivo transdermal iontophoretic delivery of growth hormone releasing factor GRF (1-44) in hairless guinea pigs. J. Control. Rel. 18:213-220 (1992).
15. G. L. Li. Transdermal Iontophoretic Delivery of R-Apomorphine for the Treatment of Patients with Parkinson's Disease. Ph.D. Thesis, Leiden University, Leiden, The Netherlands, 2003.
16. A. Jadoul, J. Mesens, W. Caers, F. de Beukelaar, R. Crabbe, and V. Preat. Transdermal permeation of alniditan by iontophoresis: in vitro optimization and human pharmacokinetic data. Pharm. Res. 13:1348-1353 (1996).
17. WinNonlin Professional v. 4.1. Pharsight Corporation, Mountain View, CA. (2003).
18. G. L. Li, A. Grossklaus, M. Danhof, and J. A. Bouwstra. Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: in vitro validation studies. Int. J. Pharm. 266:61-68 (2003).
19. R. Van der Geest, T. Van Laar, J. M. Gubbens-Stibbe, H. E. Bodde, and M. Danhof. Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. Pharm. Res. 14:1804-1810 (1997).
20. A. K. Nugroho, G. L. Li, M. Danhof, and J. A. Bouwstra. Transdermal iontophoresis of rotigotine across human stratum corneum in vitro: influence of pH and NaCl concentration. Pharm. Res. 21:844-850 (2004).
21. R. Van der Geest, M. Danhof, and H. E. Bodde.!Iontophoretic delivery of apomorphine. I: In vitro optimization and validation. Pharm. Res. 14:1798-1803 (1997).
22. L. Finkelstein and E. R. Carson. Mathematical Modeling of Dynamic Biological Systems, 2nd ed. John Wiley & Sons, New York, 1985.
23. S. Grond, L. Radbruch, and K. A. Lehmann. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin. Pharmacokinet. 38:59-89 (2000).